Voltage-gated calcium channels: Their discovery, function and importance as drug targets

Annette C. Dolphin

Abstract
This review will first describe the importance of Ca\(^{2+}\) entry for function of excitable cells, and the subsequent discovery of voltage-activated calcium conductances in these cells. This finding was rapidly followed by the identification of multiple subtypes of calcium conductance in different tissues. These were initially termed low- and high-voltage activated currents, but were then further subdivided into L-, N-, P/Q-, R- and T-type calcium currents on the basis of differing pharmacology, voltage-dependent and kinetic properties, and single channel conductance. Purification of skeletal muscle calcium channels allowed the molecular identification of the pore-forming and auxiliary \(\alpha_2\delta, \beta\) and \(\gamma\) subunits present in these calcium channel complexes. These advances then led to the cloning of the different subunits, which permitted molecular characterisation, to match the cloned channels with physiological function. Studies with knockout and other mutant mice then allowed further investigation of physiological and pathophysiological roles of calcium channels. In terms of pharmacology, cardiovascular L-type channels are targets for the widely used antihypertensive 1,4-dihydropyridines and other calcium channel blockers, N-type channels are a drug target in pain, and \(\delta\)-1 is the therapeutic target of the gabapentinoid drugs, used in neuropathic pain. Recent structural advances have allowed a deeper understanding of Ca\(^{2+}\) permeation through the channel pore and the structure of both the pore-forming and auxiliary subunits. Voltage-gated calcium channels are subject to multiple pathways of modulation by G-protein and second messenger regulation. Furthermore, their trafficking pathways, subcellular localisation and functional specificity are the subjects of active investigation.

Keywords
Calcium, channel, voltage, second messenger, neuron, heart

Received: 12 February 2018; accepted: XXX

Introduction: the importance of Ca\(^{2+}\) entry for function of excitable cells
It has been clear from the time of Sydney Ringer, working at University College London, that calcium ions (Ca\(^{2+}\)) are essential for heart muscle contraction (Ringer, 1883). However, the paramount importance of Na\(^{+}\) and K\(^{+}\) for the activation and inactivation of action potential generation led to Ca\(^{2+}\) permeation being little studied for many years. In the 1950’s Paul Fatt, working at University College London with both Katz and Ginsborg, found that Ca\(^{2+}\) supports action potential-like spikes in crustacean muscle (Fatt and Ginsborg, 1958; Fatt and Katz, 1953), and this was also found to be true in barnacle muscle (Hagiwara and Takahashi, 1967). When it was also identified that Ca\(^{2+}\) was essential for neurotransmitter release (Katz and Miledi, 1967), it became clear that calcium ion entry through membranes was key to many important processes in nerves as well as muscle. These key players in the field are pictured in Figure 1(a)–(d).

Identification of multiple subtypes of calcium channel
A major contribution to the understanding of calcium channel function then came from Harald Reuter (Figure 1(e)), who showed, using microelectrodes, that calcium currents were present in voltage-clamped cardiac Purkinje fibres (Reuter, 1967). The advent of the gigaseal patch-clamp method for recording currents through the membrane of single cells (Hamill et al., 1981) then allowed single calcium channels to be resolved (Fenwick et al., 1982).

The discovery and use of verapamil, and the 1,4-dihydropyridines (DHPs) including nifedipine, as antihypertensive drugs represented a very important advance (Fleckenstein, 1983) (Figure 1(f)). Their target was found to be inhibition of cardiovascular calcium channels (Lee and Tsien, 1983); thus, the term calcium channel blocker or antagonist was coined. Related drugs were found to have agonist effects (Schramm et al., 1983), to increase cardiac calcium conductance and prolong single channel openings (Hess et al., 1984). Both the agonist and antagonist...
drugs gave researchers important tools to dissect calcium channel function in a variety of tissues.

The first suggestion that there was more than one component to calcium currents in different tissues came from the group of Hagiwara et al. (1975), followed by evidence of low threshold Ca\(^{2+}\) spikes in mammalian central neurons (Llinás and Yarom, 1981), and distinct low voltage-activated currents in peripheral dorsal root ganglion neurons (Carbone and Lux, 1984; Fedulova et al., 1985; Nilius et al., 1985).

Identification of N-, P- and R-type calcium currents as distinct from L-type channels

In dorsal root ganglion (DRG) neurons, it was then found that there were three calcium current components. The DHP-sensitive current was designated L-type (for long-lasting, which also had a large single channel conductance) and the low-voltage activated component was termed T (for transient, which also had a Tiny single channel conductance). A third component, which was high-voltage activated but DHP-insensitive, was termed N-type (neither L nor T, and also exclusively Neuronal) (Fox et al., 1987; Nowycky et al., 1985) (Figure 2(a)). A blocker of this component was not long in appearing. A toxin component from the marine snail Conus geographus, ω-conotoxin GVIA, first thought to block both neuronal L- and N-type calcium currents (McCleskey et al., 1987), was later found to be highly selective for N-type channels (Boland et al., 1994; Plummer et al., 1989). Using this pharmacological blocker, N-type calcium currents were then shown to play a key role in neurotransmitter release (Hirning et al., 1988).

The importance of pharmacological tools in the discovery of calcium channel subtypes became even more evident when it was found that the calcium current in Purkinje neurons was not blocked by DHPs or by ω-conotoxin GVIA. This current was called P-type (for Purkinje) (Llinás et al., 1989). The same group used a polyamine toxin (FTX) from the American funnel web spider to block Purkinje cell Ca\(^{2+}\) currents, but FTX was not particularly selective for P-type channels, whereas a peptide toxin component from the same spider (ω-agatoxin IVA) was more selective, blocking fully the calcium current in Purkinje neurons (Mintz et al., 1992). This toxin also inhibited a component of the calcium current in cerebellar granule cells (Pearson et al., 1995;
Randall and Tsien, 1995), which was initially termed Q-type as it had different biophysical properties from that in Purkinje neurons (Randall and Tsien, 1993); however, these are usually now called PQ currents. That study also identified an additional resistant current component in cerebellar granule cells which was designated R-type (Randall and Tsien, 1995), and a similar novel component was also identified in bullfrog sympathetic neurons (Elmslie et al., 1994). A tarantula toxin, SNX-482, was identified to block this component (Newcomb et al., 1998), but it has subsequently been found also to block other channels (Kimm and Bean, 2014), complicating interpretation of physiological experiments using SNX-482.

**Purification and molecular identification of the calcium channel subtypes**

Receptors for the DHP calcium antagonists were identified using [3H]-nitrendipine to guide purification. They were found to be highly concentrated in the t-tubules of skeletal muscle (Fosset et al., 1983), where they were shown to be responsible for charge movement and excitation-contraction coupling (Rios and Brum, 1987). Purification studies identified the skeletal muscle DHP receptor to be a complex of five polypeptides in approximately equal amounts, and therefore considered to be subunits. They were termed, in decreasing order of size, the α1, α2, β, γ and δ subunits (Hosey et al., 1987; Takahashi et al., 1987). The 175 kDa α1 subunit was tentatively identified as the pore-forming subunit of the channel, since it bound radiolabelled DHP. The associated proteins were termed auxiliary or accessory subunits.

Peptide sequence from the purified DHP receptor protein enabled the identification of probes and subsequent cloning of the skeletal muscle calcium channel (Ellis et al., 1988; Tanabe et al., 1987). The hydropathy plot indicated that it was a 24 transmembrane spanning protein, with four homologous repeated domains joined by intracellular linkers, similar to recently cloned voltage-gated Na+ channel (Noda et al., 1984) (Figure 2(b)). This protein was termed α1S (for skeletal muscle) and was indisputably shown to encode a calcium channel by injection of its cDNA into dysgenic skeletal myotubes which lack the mRNA for α1S (Tanabe et al., 1988). This restored excitation–contraction coupling, as well as the very slow calcium current observed in native skeletal muscle.

The cardiac L-type calcium channel, termed α1C, was then cloned by homology with α1S (Mikami et al., 1989). Prior to this time, the unique permeation selectivity of the voltage-gated calcium channels for Ca2+ had already been attributed to high affinity Ca2+ binding in the pore of the channel (Hess and Tsien, 1984), and this was borne out by identification of key glutamate residues in the pore 'P loops' (Yang et al., 1993), whose acidic side chains were surmised to participate in Ca2+ (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)2+ binding and permeation.

Several brain calcium channels were then cloned and identified to encode P- and N-type channels (Mori et al., 1991; Snutch et al., 1990; Starr et al., 1991). These were termed α1A and α1B, respectively. Another channel was cloned and dubbed α1E (Soong et al., 1993). It was first classified as a low-voltage activated T-type channel, but it soon became clear that it did not have the expected properties, and it is now considered to encode R-type channels. Genes for three T-type channels were later cloned by Perez-Reyes and colleagues (Cribbs et al., 1998; Lee et al., 1999; Perez-Reyes et al., 1998). These were termed α1G, H and I. In addition, two further L-type channels were identified. The first, cloned from brain, was called α1D (Williams et al., 1992) and was shown to have distinctive biophysical properties, being lower voltage-activated than α1C (Koschak et al., 2001; Xu and Lipscombe, 2001). Finally, a fourth L-type channel was identified because of its role in a genetic form of night blindness (Bech et al., 1998; Strom et al., 1998), and this was also shown to have properties distinguishing it from the other L-type channels (Koschak et al., 2003).

Following the cloning and initial study of all the calcium channel α1 subunits identified in the mammalian genome, a rationalised nomenclature was adopted in 2000, grouping the α1 subunits into Ca1.1 (L-type), Ca1.2 (non-L-type) and Ca1.3 (T-type) (Ertel et al., 2000) (Table 1). Since that time the distinctive properties of multiple splice variants of these channels have also been recognised.

**Importance of auxiliary subunits**

The auxiliary β subunit from skeletal muscle was the first to be cloned (Ruth et al., 1989) (Figure 2(b)). It was subsequently termed β1, after three further isoforms (β2, β3 and β4) as well as multiple splice variants were identified by homology. β1 is the non-muscle splice variant of B1 (Pagnill et al., 1991), and β2 is a palmitoylated β1 splice variant, giving it distinctive properties (Qin et al., 1998). The importance of these β subunits to the expression of the Ca1.1 and Ca1.2 channels was clear from antisense knockdown studies in native tissues and early expression studies (Berrow et al., 1995; Qin et al., 1998). In contrast, the Ca1.3 channels do not appear to have any obligate auxiliary subunits.

When the auxiliary α1,δ subunit was cloned, it was realised that α1 and δ are encoded by the same gene and form a pre-protein, which is then proteolytically cleaved, but the α1 and δ proteins remain associated by pre-formed disulphide bonding (De Jongh et al., 1990; Jay et al., 1991). Its proteolytic cleavage has recently been shown to be essential for α1,δ function (Kadurin et al., 2016). The skeletal muscle α1,δ was subsequently termed α1,δ-1, when three further mammalian isoforms were identified: α1,δ-2 (Barclay et al., 2001; Gao et al., 2000), α1,δ-3 and α1,δ-4 (Qin et al., 2002). The muscle α1,δ subunit was first described as a transmembrane protein, but they have subsequently been shown to be glycospomatidylinositol (GPI)-anchored into the outer leaflet of the plasma membrane (Davies et al., 2010) (Figure 2(b)). The α1,δ subunit was predicted to contain a von Willebrand factor A (VWA) domain, which was found to be essential for trafficking, both of α1,δ itself, and for its effect on the α1 subunits (Canti et al., 2005; Cassidy et al., 2014; Hoppa et al., 2012).

The skeletal muscle calcium channel complex also contains a γ subunit, now called γ1 (Takahashi et al., 1987) (Figure 2(b)), but γ is not associated with other calcium channels, and further members of this ‘γ subunit’ family are now known to be trafficking proteins that modulate the function of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptors, rather than voltage-gated calcium channel subunits (Tomita et al., 2003). The roles of the different calcium channel auxiliary proteins and their interaction with the α1 subunits are summarised in Table 1.
subunits have been more extensively reviewed recently (Dolphin, 2012).

**Elucidation of physiological channel function from knockout mouse studies and genetic mutations**

Several spontaneously arising mouse loss-of-function mutants were identified which gave important clues as to the function of the channel subunits. This was particularly true for CaV2.1, β4 and αδ-2 which are strongly expressed in cerebellum, and whose mutation produced obvious ataxias (Barclay et al., 1991; Burgess et al., 1997; Fletcher et al., 1996). Subsequent targeted knockouts gave similar phenotypes. A surprise came with the knockout of CaV1.3, both in mice and in a homozygous human mutation, in whom the main phenotype was deafness and sino-atrial node dysfunction (Baig et al., 2011). Furthermore CaV1.4 was identified from its role in a retinal disease (Bech-Hansen et al., 1998; Strom et al., 1998), and the knockout mouse has a similar phenotype (Mansergh et al., 2005). Knockout of CaV2.2 resulted in a diminution of neuropathic pain responses, reinforcing its importance in primary afferent neurotransmission (Saegusa et al., 2003). Similarly, αδ-1 knockout delayed the onset of mechanical hyperalgesia following neuropathic injury (Patel et al., 2013) and αδ-3 has a role in hearing (Pirone et al., 2014), and in the central control of pain (Neely et al., 2010).

**Structural studies**

The first components of the calcium channel complex to be amenable to structural studies were the β subunits, which contain two conserved interacting domains (SH3 and guanylate kinase-like), the latter binding to the linker between domains I and II of the channels (Chen et al., 2004; Opatowsky et al., 2004; Pragnell et al., 1994; Richards et al., 2004; Van Petegem et al., 2004).

The first crystal structure for a calcium-selective voltage-gated channel was obtained using a mutant form of a bacterial sodium channel homolog, NaVAb, a single domain channel which forms homo-tetramers (Payandeh et al., 2011). This was mutated so that the pore became Ca2+-selective, forming CaVAb. This structure has provided multiple insights, including confirmation of the Ca2+ permeation process (Tang et al., 2014). Remarkably, this channel was sensitive to calcium channel antagonists, yielding further important insight into the binding and mechanism of action of these drugs (Tang et al., 2016). For mammalian calcium channel complexes, although low-resolution single particle electron microscopic structures were published previously (Serysheva et al., 2002; Walsh et al., 2009; Wolf et al., 2003), major advances in cryo-electron microscopy were needed before a detailed structure of the skeletal muscle calcium channel was produced, very beautifully elucidating details of the pore and the subunit arrangement (Wu et al., 2016). GPI-anchoring of αδ (Davies et al., 2010), and interaction of the α1 subunit with the VWA and Cache domains (which have similarity to bacterial chemotaxis domains) of αδ (Canti et al., 2010), were confirmed in the structure (Wu et al., 2016).

**Calcium channel modulation**

Only two canonical second messenger modulation pathways will be considered here, for reasons of space: inhibitory modulation of neuronal calcium channels by G-proteins, and cyclic AMP-dependent phosphorylation, mediating enhancement of L-type channels. Many other pathways also deserve mention, including Ca2+-calmodulin control of Ca2+-dependent inactivation and facilitation of L-type and P-type channels, studied extensively by the late David Yue (Dick et al., 2008; Peterson et al., 1999).

**G-protein modulation**

Voltage-dependent activation of neuronal calcium channels is required for neurotransmitter release, and this process can be inhibited by a range of modulatory neurotransmitters coupled to seven-transmembrane receptors (Dolphin, 1982; Jessell and Iversen, 1977; Peng and Frank, 1989), leading to the view that inhibitory modulation of the calcium channel-mediated component of the presynaptic action potential underpins receptor-mediated presynaptic inhibition (Dolphin et al., 1986; Dunlap and Fischbach, 1978; Ikeda and Schofield, 1989) (Figure 3(a)). Modulation of neurotransmitter release was found to be mediated by a pertussis toxin-sensitive GTP-binding protein, of the G i/G o family (Dolphin and Prestwich, 1985). The inhibitory
Cyclic AMP-dependent phosphorylation

Another key example of second messenger modulation is provided by L-type calcium channels, which are potentiated by β-adrenergic receptor activation, via a cyclic AMP-dependent mechanism (Cachelin et al., 1983; Reuter, 1983). In heart, this effect is mediated by β1-adrenergic receptors and forms one of the main components of the fight-or-flight response. However, it has been difficult to reproduce when cloned Ca\(_{\text{v}}\)1.2 calcium channels are expressed, for example, in HEK-293 cells, suggesting it is more complex than simple channel phosphorylation, and indeed, the role of the several protein kinase A substrate serines in cardiac Ca\(_{\text{v}}\)1.2 function is still being determined (Lemke et al., 2008; Yang et al., 2016).

Furthermore, the response to β-adrenergic stimulation may involve a proteolytically cleaved C-terminal fragment of the endogenous Ca\(_{\text{v}}\)1.2 channels (Fu et al., 2013; Fuller et al., 2010). Perhaps surprisingly, there appears to be a somewhat different basis for the spatially restricted stimulation observed in hippocampal neurons following activation by β2-adrenergic receptors of neuronal Ca\(_{\text{v}}\)1.2 channels (Qian et al., 2017).

Future research

The selective pharmacology that has been so important for dissecting out the functions of different calcium channels is still incomplete. Although a selective inhibitor of the T-type calcium channels exists (Dreyfus et al., 2010), it does not differentiate between the Ca\(_{\text{v}}\)3 channels. Similarly, there are currently no selective inhibitors of the different Ca\(_{\text{v}}\)1 channels. Such inhibitors that would be able to differentiate between these very similar channels could have important therapeutic possibilities. For example, selective inhibition of Ca\(_{\text{v}}\)3.2 could be of therapeutic benefit in certain types of pain (Marger et al., 2011), and selective inhibitors of Ca\(_{\text{v}}\)1.3 have potential for therapeutic use in Parkinson’s disease and other disorders (Striessnig et al., 2015). Furthermore, although ω-conotoxin GVIA is a selective blocker of N-type channels and a related compound is licenced for use intrathecally in some chronic pain conditions (Miljanich, 2004), no small molecule inhibitors of N-type channels have yet been shown to be effective in clinical trials for chronic pain.

Future challenges include a full understanding of how particular calcium channels are trafficked into precise subcellular domains, for example, how some channels are targeted to dendrites (Hall et al., 2013), while others are directed to presynaptic active zones to mediate neurotransmitter release (Kaeser et al., 2011). Furthermore, calcium channels have been found to interact, directly or indirectly, with multiple scaffolding proteins, ion channels and second messenger pathways (Müller et al., 2010), but how these are organised and function together remains to be elucidated. Related to this, the pathways for intracellular Ca\(^{2+}\) signalling to the nucleus and the selectivity for L-type Ca\(^{2+}\) channels in neurons are still being revealed (Cohen et al., 2015; Wheeler et al., 2012).

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

This work was supported by a Wellcome Trust Investigator award (098360/Z/12/Z) and a Royal Society Leverhulme Senior Fellowship to A.C.D.

References

Baig SM, Koschak A, Lieb A, et al. (2011) Loss of Ca(v)1.3 (CACA1D) function in a human channelopathy with bradycardia and congenital deafness. Nature Neuroscience 14: 77–84.

Barclay J, Balaguero N, Mione M, et al. (2001) Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d222 gene and decreased calcium channel current in cerebellar Purkinje cells. Journal of Neuroscience 21: 6095–6104.
membrane patches. *Pflügers Archiv: European Journal of Physiology* 391: 85–100.

Herlitze S, Garcia DE, Mackie K, et al. (1996) Modulation of Ca2+ channels by G-protein β gamma subunits. *Nature* 380: 258–262.

Hess P and Tsien RW (1984) Mechanism of ion permeation through calcium channels. *Nature* 309: 453–456.

Hess P, Lansman JB and Tsien RW (1984) Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. *Nature* 311: 538–544.

Hirning LD, Fox AP, McCleskey EW, et al. (1988) Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. *Science* 239: 57–60.

Holz GGI, Rane SG and Dunlap K (1986) GTP-binding proteins mediate transmitter inhibition of voltage-dependent calcium channels. *Nature* 319: 670–672.

Hoppa MB, Lana B, Margas W, et al. (2012) Alpha2delta expression sets presynaptic calcium channel abundance and release probability. *Nature* 486: 122–125.

Hosey MM, Barhanin J, Schmid A, et al. (1987) Photaffinity labelling and phosphorylation of a 165 kilodalton peptide associated with dihydropyridine and phenylalkylamine-sensitive calcium channels. *Biochemical and Biophysical Research Communications* 147: 1137–1145.

Ikeda SR (1996) Voltage-dependent modulation of N-type calcium channels by G-protein beta gamma subunits. *Nature* 380: 255–258.

Ikeda SR and Schofield GG (1989) Somatostatin blocks a calcium current in rat sympathetic ganglion neurons. *Journal of Physiology* 409: 221–240.

Jay SD, Sharp AH, Kahl SD, et al. (1991) Structural characterization of the dihydropyridine-sensitive calcium channel α2 subunit and the associated delta peptides. *Journal of Biological Chemistry* 266: 3287–3293.

Jessell TM and Iversen LL (1977) Opiate analgesics inhibit substance P action. *Cell* 19: 1912–1921.

Kadurin I, Ferron L, Rothwell SW, et al. (2016) Proteolytic maturation of the dihydropyridine-sensitive calcium channel α1B subunit. *Neuroreport* 27: 22100–22106.

Kaschak A, Reimer D, Huber I, et al. (2001) Alpha1D (Cav1.3) subunits form L-type Ca2+ channels activating at negative voltages. *Journal of Biological Chemistry* 276: 22100–22106.

Kaschak A, Reimer D, Walter D, et al. (2003) Cav1.4 alpha1 subunits can form slowly inactivating dihydropyridine-sensitive L-type Ca2+ channels lacking Ca2+-dependent inactivation. *The Journal of Neuroscience* 23: 6041–6049.

Lee J-H, Daud AN, Cribbs LL, et al. (1999) Cloning and expression of a novel member of the low voltage activated T type calcium channel family. *Journal of Neuroscience* 19: 1912–1921.

Lee KS and Tsien RW (1983) Mechanism of calcium channel blockade by verapamil, D600, dilantin and nimodipine in single dialysed heart cells. *Nature* 302: 790–794.

Lemke T, Welling A, Christel CJ, et al. (2008) Unchanged beta-adrenergic stimulation of cardiac L-type calcium channels in Cav1.2 phosphorylation site S1928A mutant mice. *Journal of Biological Chemistry* 283: 34738–34744.

Linlés R and Yaron Y (1981) Electrophysiology of mammalian inferior olivary neurones in vitro. Different types of voltage-dependent ionic conductances. *The Journal of Physiology* 315: 549–567.

Linlés R, Sugimori M, Lin J-W, et al. (1989) Blocking and isolation of a calcium channel from neurons in mammals and cephalopods utilizing a toxin fraction (FTX) from funnel-web spider poison. *Proceedings of the National Academy of Sciences of the United States of America* 86: 1689–1693.

McCleskey EW, Fox AP, Feldman DH, et al. (1987) Omega-conotoxin: Direct and persistent blockade of specific types of calcium channels in neurons but not muscle. *Proceedings of the National Academy of Sciences of the United States of America* 84: 4327–4331.

Mansergh F, Orton NC, Vessey JP, et al. (2005) Mutation of the calcium channel gene Cacna1f disrupts calcium signaling, synaptic transmission and cellular organization in mouse retina. *Human Molecular Genetics* 14: 3035–3046.

Margé F, Gélot A, Alloua A, et al. (2011) T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. *Proceedings of the National Academy of Sciences of the United States of America* 108: 11268–11273.

Meir A, Bell DC, Stephens GJ, et al. (2000) Calcium channel beta subunit promotes voltage-dependent modulation of α1B by Gβγ. *Biophysical Journal* 79: 731–746.

Mikami A, Inoto K, Tanabe T, et al. (1989) Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. *Nature* 340: 230–233.

Miljanich GP (2004) Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. *Current Medicinal Chemistry* 11: 3029–3040.

Mintz IM, Venema VJ, Swiderkem KM, et al. (1992) P-type calcium channels blocked by the spider toxin w-Aga-IVA. *Nature* 355: 827–829.

Mori Y, Friedrich T, Kim MS, et al. (1991) Primary structure and functional expression from complementary DNA of a brain calcium channel. *Nature* 350: 398–402.

Müller CS, Haupt A, Bild W, et al. (2010) Quantitative proteomics of the Cav2 channel nano-environments in the mammalian brain. *Proceedings of the National Academy of Sciences of the United States of America* 107: 14950–14957.

Neeley GG, Hess A, Costigan M, et al. (2010) A genome-wide Drosophila screen for heat nociception identifies alpha2delta3 as an evolutionarily conserved pain gene. *Cell* 143: 628–638.

Newcomb R, Szoke B, Palma A, et al. (1998) Selective peptide antagonist of the class E calcium channel from the venom of the tarantula *Hysterocrates gigas*. *Biochemistry* 37: 15353–15362.

Nilius B, Hess P, Lansman JB, et al. (1985) A novel type of cardiac calcium channel in ventricular cells. *Nature* 316: 443–446.

Noda M, Shimizu S, Tanabe T, et al. (1984) Primary structure of electrophorus electricus sodium channel deduced from cDNA sequence. *Nature* 312: 121–127.

Nowacky MC, Fox AP and Tsien RW (1985) Three types of neuronal calcium channel with different calcium agonist sensitivity. *Nature* 316: 440–446.

Opatomsky Y, Chen CC, Campbell KP, et al. (2004) Structural analysis of the voltage-dependent calcium channel beta subunit functional core and its complex with the alpha interaction domain. *Neuron* 42: 387–399.

Page KM, Canti C, Stephens GJ, et al. (1998) Identification of the amino terminus of neuronal Ca2+ channel α1 subunits α1B and α1E as an essential determinant of G protein modulation. *Journal of Neuroscience* 18: 4815–4824.

Patel R, Bauer CS, Nieto-Rostro M, et al. (2013) alpha2delta-1 gene deletion affects somatosensory neuron function and delays mechanical hypersensitivity in response to peripheral nerve damage. *The Journal of Neuroscience* 33: 16412–16426.

Payande J, Scheuer T, Zheng N, et al. (2011) The crystal structure of a voltage-gated sodium channel. *Nature* 475: 353–358.

Pearson HA, Sutton KG, Scott RH, et al. (1995) Characterization of Ca2+ channel currents in cultured rat cerebellar granule neurones. *Journal of Physiology* 482: 493–509.

Peng YY and Frank E (1989) Activation of GABAB receptors causes presynaptic inhibition at synapses between muscle spindle afferents and motoneurons in the spinal cord of bullfrogs. *Journal of Neuroscience* 9: 1502–1515.
Perez-Reyes E, Cribs LL, Daud A, et al. (1998) Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. *Nature* 391: 896–900.

Peterson BZ, DeMaria CD and Yue DT (1999) Calmodulin is the Ca²⁺ sensor for Ca²⁺-dependent inactivation of L-type calcium channels. *Neuron* 22: 549–558.

Pirone A, Kurt S, Zuccotti A, et al. (2014) alpha2delta3 is essential for normal structure and function of auditory nerve synapses and is a novel candidate for auditory processing disorders. *The Journal of Neuroscience* 34: 434–445.

Plummer MR, Logothetis DE and Hess P (1989) Elementary properties and pharmacological sensitivities of calcium channels in mammalian peripheral neurons. *Neuron* 2: 1453–1463.

Pragnell M, De Waard M, Mori Y, et al. (1994) Calcium channel β-subunit binds to a conserved motif in the I-II cytoplasmic linker of the α₁-subunit. *Nature* 368: 67–70.

Pragnell M, Sakamoto J, Jay SD, et al. (1991) Cloning and tissue-specific expression of the brain calcium channel β-subunit. *FEBS Letters* 291: 253–258.

Qian H, Patriarchi T, Price JL, et al. (2017) Phosphorylation of Ser1928 mediates the enhanced activity of the L-type Ca²⁺ channel Cav1.2 by the beta2-adrenergic receptor in neurons. *Science Signaling* 10: eaap9659.

Qin N, Platano D, Olcese R, et al. (1998) Unique regulatory properties of the type 2a Ca²⁺ channel β subunit caused by palmitylation. *Proceedings of the National Academy of Sciences of the United States of America* 95: 4690–4695.

Qin N, Yagel S, Momplaisir ML, et al. (2002) Molecular cloning and characterization of the human voltage-gated calcium channel α₆δ-4 subunit. *Molecular Pharmacology* 62: 485–496.

Randall A and Tsien RW (1995) Pharmacological dissection of multiple types of Ca²⁺ channel currents in rat cerebellar granule neurons. *Journal of Neuroscience* 15: 2995–3012.

Reuter H (1967) The dependence of slow inward current in Purkinje fibres on the extracellular calcium-concentration. *The Journal of Physiology* 192: 479–492.

Reuter H (1983) Calcium channel modulation by neurotransmitters, enzymes and drugs. *Nature* 301: 569–574.

Richards MW, Butcher AJ and Dolphin AC (2004) Calcium channel beta subunits: Structural insights AID our understanding. *Trends in Pharmacological Sciences* 25: 626–632.

Ringer S (1883) A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart. *The Journal of Physiology* 4: 29–4223.

Rios E and Brum G (1987) Involvement of dihydropyridine receptors in excitation-contraction coupling in skeletal muscle. *Nature* 325: 717–720.

Ruth P, Röhrkasten A, Biel M, et al. (1989) Primary structure of the β subunit of the DHP-sensitive calcium channel from skeletal muscle. *Science* 245: 1115–1118.

Saegusa H, Kurihara T, Zong S, et al. (2001) Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2⁺ channel. *Nature* 414: 223–22321.

Scharfman E, Thomas G, Towart R, et al. (1983) Novel dihydropyridines with positive inotropic action through activation of Ca²⁺ channels. *Journal of Biological Chemistry* 258: 1112–1124.

Scott RH and Dolphin AC (1986) Regulation of calcium currents by a GTP analogue: potentiation of (-)-baclofen-mediated inhibition. *Neurosci Lett* 69: 59–64.

Seresheva II, Ludtke SJ, Baker MR, et al. (2002) Structure of the voltage-gated L-type Ca²⁺ channel by electron cryomicroscopy. *Proceedings of the National Academy of Sciences of the United States of America* 99: 10370–10375.

Snutch TP, Leonard JP, Gilbert MM, et al. (1990) Rat brain expresses a heterogeneous family of calcium channels. *Proceedings of the National Academy of Sciences of the United States of America* 87: 3391–3395.

Soong TW, Stea A, Hodgson CD, et al. (1993) Structure and functional expression of a member of the low voltage-activated calcium channel family. *Science* 260: 1133–1136.

Starr TVB, Prystaw Y and Snutch TP (1991) Primary structure of a calcium channel that is highly expressed in the rat cerebellum. *Proceedings of the National Academy of Sciences of the United States of America* 88: 5621–5625.

Striessnig J, Ortner NJ and Pinggera A (2015) Pharmacology of L-type calcium channels: Novel drugs for old targets? *Current Molecular Pharmacology* 8: 110–122.

Strom TM, Nyakatura G, Apfelstedt Sylla E, et al. (1998) An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness. *Nature Genetics* 19: 260–263.

Takahashi M, Seager MJ, Jones IF, et al. (1987) Subunit structure of dihydropyridine-sensitive calcium channels from skeletal muscle. *Proceedings of the National Academy of Sciences of the United States of America* 84: 5478–5482.

Tanabe T, Beam KG, Powell JA, et al. (1988) Restoration of excitation-contraction coupling and slow calcium current in dyssgenic muscle by dihydropyridine receptor complementary DNA. *Nature* 336: 134–139.

Tanabe T, Takeda H, Mikami A, et al. (1987) Primary structure of the receptor for calcium channel blockers from skeletal muscle. *Nature* 328: 313–318.

Tang L, Gamal El-Din TM, Payandeh J, et al. (2014) Structural basis for Ca²⁺ selectivity of a voltage-gated calcium channel. *Nature* 505: 56–61.

Tang L, Gamal El-Din TM, Swanson TM, et al. (2016) Structural basis for inhibition of a voltage-gated Ca²⁺ channel by Ca²⁺ antagonist drugs. *Nature* 537: 117–121.

Tomita S, Chen L, Kawasaki Y, et al. (2003) Functional studies and distribution define a family of transmembrane AMPA receptor regulatory proteins. *Journal of Cell Biology* 161: 805–816.

Van Petegem F, Clark KA, Chatelain FC, et al. (2004) Structure of a complex between a voltage-gated calcium channel beta-subunit and an alpha-subunit domain. *Nature* 429: 671–675.

Walsh CP, Davies A, Butcher AJ, et al. (2009) 3D structure of CaV3.1: Comparison with the cardiac L-type voltage-gated calcium channel monomer architecture. *Journal of Biological Chemistry* 284: 22310–22321.

Wheeler DG, Groth RD, Ma H, et al. (2012) Ca(V)1 and Ca(V)2 channels engage distinct modes of Ca(2+) signaling to control CREB-dependent gene expression. *Cell* 149: 1112–1124.

Williams ME, Feldman DH, McCue AF, et al. (1992) Structure and functional expression of α₁, α₂, and β subunits of a novel human neuronal calcium channel subtype. *Neuron* 8: 71–84.

Wolf M, Eberhart A, Glossmann H, et al. (2003) Visualization of the domain structure of an L-type Ca²⁺ channel using electron cryomicroscopy. *Journal of Molecular Biology* 332: 171–182.

Wu J, Yan Z, Li Z, et al. (2016) Structure of the voltage-gated calcium channel Cav1.1 at 3.6 A resolution. *Nature* 537: 191–196.

Xu WF and Lipscombe D (2001) Neuronal Ca v1.3 calcium channels: Novel candidate for auditory processing disorders. *Proceedings of the National Academy of Sciences of the United States of America* 113: E7976–E7985.